Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer.
- 1 October 1987
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 5 (10) , 1566-1573
- https://doi.org/10.1200/jco.1987.5.10.1566
Abstract
Eleven patients with hepatocellular cancer had non resectable lesions, ten as determined by laparotomy and one by computed tomographic (CT) evidence of inferior vena caval invasion. These patients were treated with a variety of new modalities, particularly radiolabeled antiferritin antibodies. Following treatment, seven of the 11 patients were considered to have converted their lesions to possible resectability. Six patients had complete resections, and one patient was partially resected. All patients had the common features of either nodular massive or nodular multifocal hepatocellular cancer. Relative to the patient''s initial status, the quality of life remains high, and a new approach in the treatment of the nodular form of nonresectable hepatoma has been demonstrated. The present rate of such conversion to resectability is unknown. However, with further advances in radiolabeled antibody therapy, these results offer a new opportunity in the management of hepatocellular cancer.This publication has 2 references indexed in Scilit:
- Distribution of and physiologic factors that affect 131I-antiferritin tumor localization in experimental hepatomaInternational Journal of Radiation Oncology*Biology*Physics, 1984
- Surgical Resection for Benign and Malignant Liver DiseaseAnnals of Surgery, 1980